Nitric oxide inhalation increases oxygen delivery after cardiovascular surgery in adult patients whether or not they have pulmonary hypertension

1998 ◽  
Vol 12 (4) ◽  
Author(s):  
Keiji Kumon ◽  
Naoki Yahagi
1999 ◽  
Vol 23 (2) ◽  
pp. 169-174 ◽  
Author(s):  
Keiji Kumon ◽  
Naoki Yahagi ◽  
Hideaki Imanaka ◽  
Muneyuki Takeuchi ◽  
Hiroshi Miyano ◽  
...  

2018 ◽  
Vol 25 (6) ◽  
pp. 2174-2176
Author(s):  
Fayçal Ben Bouallègue ◽  
Fabien Vauchot ◽  
Aurélie Bourdon ◽  
Meriem Benkiran ◽  
Clément Boissin ◽  
...  

1999 ◽  
Vol 14 (3) ◽  
pp. 133-140 ◽  
Author(s):  
Jörg Weimann ◽  
Wolfgang Zink ◽  
Philipp A. Schnabel ◽  
Heinz Jakob ◽  
Martha Maria Gebhard ◽  
...  

2022 ◽  
Vol 29 (1) ◽  
pp. 45-46
Author(s):  
Shinya Kai ◽  
Norihisa Yasuda ◽  
Yoshifumi Ochi ◽  
Takakuni Abe ◽  
Hironori Koga ◽  
...  

2016 ◽  
Vol 12 (1) ◽  
Author(s):  
Khalid A Dahiyat

Background: Inhaled nitric oxide is a drug which has been given FDA approval in 1999 but was not found prior to approval to be safe for use in premature neonates. Aim: To review and assess the studies which was done prior to its approval in order to find out what evidences the approval by the FDA was based on. Methods: A thorough search of the electronic data-base, Medline, Embase, Cinahl, Google. Conclusion: The use of this drug in treatment of the Pulmonary hypertension in premature babies is still contraversial and hold a serious untoward effects on the health, it should only used as the last ditch.


Sign in / Sign up

Export Citation Format

Share Document